GRS Home

The Growth Hormone Research Society

Pituitary

NEXT MEETING  

The Tenth International Congress of the GRS and IGF Society

Dear GRS members

The COVID-19 pandemic continues to spread rapidly around the world. This unprecedented public health emergency has forced people into a prolonged social isolation, with profound impact on their physical, mental and economic health. Governments, institutions and companies are restricting travel and all kind of events have been cancelled worldwide.

Considering all these problems, the executive committee of our society have been virtually meeting last week with the Local Organizing Committee and with a great sorrow we have decided to cancel the 10th International Congress of the GRS and IGF Societies, which was scheduled to be held this year in Foz do Iguassu, Brazil, between 13-16 November.

Although this is of great disappointment, it is strongly felt that this decision was taken in the best all round interests of our community, since speakers, sponsors and participants would face many difficulties to organize their travels, attend the congress and enjoy the meeting. We decided to postpone the 10th International Congress of the GRS and IGF Societies, and the current plan is to hold the event in 2021 in Brazil (likely in the same period of the year). Obviously, we will keep our members informed about any further developments.

We hope all our members stay healthy and will continue to support our society.

Kind regards

On behalf of the GRS council
Martin Bidlingmaier
GRS secretary

Human Growth Homone Indications


FDA approved uses of GH according to the DEA and updated in Aug 2009

http://www.deadiversion.usdoj.gov/drugs_concern/hgh.htm

In children hGH is approved for the treatment of poor growth due to Turner’s syndrome, Prader-Willi syndrome, and chronic renal insufficiency, hGH insufficiency/deficiency, for children born small for gestational age, and for idiopathic short stature. Accepted medical uses in adults include but are not limited to the treatment of the wasting syndrome of HIV/AIDS and hGH deficiency.

Updated Guidelines for GH Therapy 2003

In August 1996, the FDA approved GH for use in adult patients with GHD. The only approved indication was pituitary disease from known causes, including pituitary tumor, pituitary surgical damage, hypothalamic disease, irradiation, trauma, and reconfirmed childhood GHD. Most patients considered for GH therapy are in one of these categories. A few patients with definite GHD, however, have other kinds of pituitary-hypothalamic disease; these include patients with Sheehan’s syndrome, autoimmune hypophysitis, or hypophysitis associated with other inflammatory conditions, such as sarcoidosis..."

The US FDA has approved GH for use in the following pediatric conditions:
• Growth hormone deficiency
• Turner syndrome
• Chronic renal insufficiency
• Small for gestational age or intrauterine growth retardation
• Prader-Willi syndrome
• Continued height deficit at puberty."

New indications for GH 2005 has a table summarizing the use of growth hormone (GH) therapy in short stature both in the US and Europe:

Treatment recommended by NICE (National Institute for Clinical Excellence) guidelines 2002 in the UK
• GH deficiency, isolated or as part of multiple pituitary hormone deficiency
• Turner syndrome
• Prader Willi syndrome
• Short stature associated with chronic renal failure

Licensed indications in Europe
• GH deficiency, isolated or as part of multiple pituitary hormone deficiency
• Turner syndrome
• Prader Willi syndrome
• Short stature associated with chronic renal failure
• Short stature associated with low birth weight

Licensed in the USA, but not in Europe
• Idiopathic short stature
Short stature conditions where there have been trials of treatment with GH but outcome is not clear (not licensed indications)
• Noonan syndrome
• Skeletal dysplasia
• Rheumatoid arthritis
• Down syndrome
• Short stature associated with prolonged steroid use
• Aarskog’s syndrome

 

 

Constitution

 

Consensus Statements

 

Honorary Members

 

hGH Indications

 

Officers

IGF Society

Links